ArticleCureus2026
Vulvar Metastasis From Colorectal Adenocarcinoma: A Report of a Rare Case and Review of Diagnostic and Therapeutic Approaches.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvar metastasis from colorectal adenocarcinoma is extremely rare, with few cases reported in the literature. We present the case of a 49-year-old woman with a history of locally advanced, moderately to well-differentiated invasive adenocarcinoma of the distal rectum treated with neoadjuvant chemotherapy and abdominoperineal resection, including partial posterior vaginal wall resection. One year later, she developed a vulvar lesion associated with metrorrhagia. Pelvic magnetic resonance imaging showed an isolated vulvar lesion without pelvic recurrence. Histopathology and immunohistochemistry confirmed metastatic colorectal adenocarcinoma. A multidisciplinary decision led to systemic chemotherapy with irinotecan, leucovorin, and 5-fluorouracil plus bevacizumab. This case highlights the importance of integrating clinical evaluation, histopathology, immunohistochemistry, and imaging in diagnosing rare metastatic sites and emphasizes the role of multidisciplinary board decisions in guiding systemic therapy and optimizing patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.